TEST:

Prosigna™ Breast Cancer Prognostic Gene Signature Assay

#ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/SwA9afc0c9 (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/CAaWtnRvWn (@teamoncology)

Biology of HR+HER2- BC in very young women is different (Vs >40 yrs): ⬆️LumB/non-Luminal PAM50 subtypes; ⬆️ ROR high tumors ROR high does not predict benefit from OFS (are these not so endocrine sensitive tumors?) Great analysis from SOFT trial #ASCO2023 #ASCO23 #bcsm @LoiSher (@GaiaGriguolo)

Breast cancer has standardized signatures (PAM50, Mammaprint) so that is plausible. I would love a standard insulin measure. Whether it's output or clearance, exposure to high ins is a risk factor some diseases. Seems metabolites could be standardized too w the right gear for all (@LWellberg)

Lots of great info to sift through here PSC was created using signatures & genes 🧬 relevant to #prostatecancer building on the concept of PAM50 in breast cancer (luminal vs basal cell of origin) (@Adam_Weiner535)

Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer https://t.co/I1CPuwZA8E #bcsm #breastcancer #SABCS2022 #SABCS22 #oncology @DrLisaCarey @drivorymd @UNC ()

@GaiaGriguolo 👩🏼‍🎤 super interesting study in the setting of brain 🧠 metastatic breast cancer, showing implications of PAM50-based subtypization, beyond IHC clinical approach! @SABCSSanAntonio #SABCS2022 @EcoleCancer_MTP @iov_irccs @MonteHospMedic ()

Dr. Ma spoke about #ER+BC. In ALTERNATE, postmenopausal pts with clinical stage II/III ER+ HER2- BC were included, concluding that both PAM50 and ROR-P help us decide which is the best neoadjuvant therapy for patients. #SABCS22 @SABCSSanAntonio https://t.co/uGUXQXibaE ()

P5-02-44 Thursday @SABCSSanAntonio Efficacy analysis of CDK4/6 inhibitors in combination with endocrine therapy treatment in HR+/HER2- breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801_CDK-PREDICT study Presenter: @OrtegaTolosa ()

OT2-08-02 Wednesday @SABCSSanAntonio SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC) Presenter: @evaciruelos ()

P3-06-02 Wednesday @SABCSSanAntonio TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis Presenter: @Prat2Prat2022 ()

https://t.co/ofU63HoiOA PAM50 non-basal subtype is the most significant predictor of benefit from adjuvant capecitabine. Great traslational analysis from phase III GEICAM/CIBOMA study in early-stage TNBC @GEICAM @KAsleh ()

One more time, the molecular subtypes matters: The pathological classification is like a photogram and the molecular subtype the film. Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine https://t.co/TfRJiJdoBd ()

@Dra_CVillarreal although is TNBC, pam50 to define cape benefit ()

Optimizing #adjuvant capecitabine in #TNBC Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. https://t.co/Gl6mfcwHwO ()

Which TNBC patients truly benefit from adjuvant capecitabine? In this interesting prespecified PAM50 analysis from the phase III GEICAM/CIBOMA, only patients with non-basal tumors (16%) benefited from capecitabine. #bcsm https://t.co/xv1nBviOfF ()

From research standpoint, Pam50 subtyping definitely identifies true basal-like in context of TNBCs. Should be included in clinical practice. We see its wide relevance/benefits across breast cancer spectrum. ()

I have not been using PAM50 but I would love to know what profiles people are using for mTNBC! ()

There’s a lot of talk about PAM50 molecular subtyping in metastatic #TNBC (#mTNBC). Do you use it in clinical practice? #breastcancer #oncologists ()

2/ #SABCS21 Tour de Force by @DrLisaCarey: #TNBC Pitfalls and Progress👏👏 Intrinsic Subtypes: Most basal👉Mut Immune gene activ/express higher TILs prognostic; & predictive chemo. Impact of spatial distribution in ME interesting. PS: PAM50: HER2e can we target? @OncoAlert (@NicoleKuderer)

Basal-like is defined by intrinsic sub-typing (PAM50). While we associate basal w/ triple negative, TNBC is defined by immunohistochemistry (IHC). IHC=standard practice, PAM50=not routine. Correlation btwn IHC defined breast CA (TNBC, HR+ etc) & PAM50 (basal, luminal A/B) is poor (@DrSGraff)

3) Poster Discussion: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies @FAndreMD (@prat_aleix)

"Veracyte’s Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy https://t.co/fpifte5wlr" (@MaglioccoTony)